MTC-NL5

MTC-NL5 is a preclinical-stage transdermal drug candidate being developed by Biotts for the treatment of pain. The asset utilizes Biotts' proprietary Multilayer Transdermal Carrier (MTC) technology, which is designed to enable the delivery of active pharmaceutical ingredients through the skin barrier into the bloodstream or local tissues. The MTC platform aims to provide controlled and sustained release of the therapeutic agent, potentially improving bioavailability and reducing systemic side effects compared to oral administration. While the specific active ingredient for MTC-NL5 is not explicitly named in public pipeline summaries, the "NL" designation in Biotts' nomenclature is frequently associated with naltrexone-based formulations, though NL5 is specifically positioned for analgesic indications.